NCT04612699

A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Jaktinib in Patients With Moderate-to-Severe Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 123 (actual)
• Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is study designed to investigate the efficacy and safety of Jaktinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index (PASI) score and routine safety assessments.

Conditions

• Moderate-to-Severe Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	Jaktinib	Administered orally
DRUG	Placebo	Administered orally

Timeline

• Start date: 2021-03-11
• Primary completion: 2022-08-15
• Completion: 2022-08-15
• First posted: 2020-11-03
• Last updated: 2025-02-20

Locations

1 site across 1 country: China